Cyclin D1, like p16INK4 (p16) and retinoblastoma (RB) proteins, participates in the cell cycle control at the G1–S transition. We have previously demonstrated altered p16 and RB protein status in non-small-cell lung cancers (NSCLCs) and their potential synergistic effect with altered p53 protein on proliferative activity (Kinoshita et al (1996) Cancer Res 56: 5557–5562). In the present study, cyclin D1 expression was studied by immunohistochemistry in the same cohort of 111 resected NSCLCs as in our previous study, and the amount of the cyclin D1 gene was analysed by Southern blot analysis in 29 NSCLCs. Cyclin D1 expression was analysed in relation to the status of p53, p16 and RB proteins, and proliferative activity determined by the Ki-67 index. It was also analysed in relation to survival of 77 patients with NSCLCs which were potentially curatively resected between 1990 and 1995. We found that: (1) cyclin D1 was expressed in 13 (11.7%) of 111 NSCLCs; (2) the cyclin D1 gene was neither significantly amplified nor rearranged; (3) cyclin D1 expression significantly correlated with altered p53 protein expression (P = 0.04), whereas it did not correlate with p16 and RB protein status; (4) proliferative activity tended to be higher in cyclin D1-positive (+) tumours than in cyclin D1-negative (–) tumours, although this difference was not statistically significant (P = 0.08); and (5) patients with cyclin D1+ tumours survived longer than patients with cyclin D1– tumours (5-year survival rates, 89% and 64% respectively, by the Kaplan–Meier method; P = 0.045 by the log-rank test), and cyclin D1 expression tended to be a favourable prognostic factor (P = 0.08 in univariate analysis). These findings suggest the involvement of cyclin D1 in the development and progression of NSCLCs, their proliferative activity and clinical outcome of NSCLC patients.
Åkervall, J. A., Michalides, RJAM, Mineta, H., Balm, A., Borg, A., Dictor, M., Jin, Y., Loftus, B., Mertens, F. & Wennerberg, J. P. (1997). Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79: 380–389.
Bartkova, J., Lukas, J., Strauss, M. & Bartek, J. (1994). Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 172: 237–245.
Beahrs, O. H., Henson, D. E., Hutter, R. V. P. & Kennedy, B. J. (1992). Lung. In Manual for Staging of Cancer, 4th edn. American Joint Committee on Cancer: Chicago 115–122.
Betticher, D. C., Heighway, J., Hasleton, P. S., Altermatt, H. J., Ryder, W. D. J., Cerny, T. & Thatcher, N. (1996). Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73: 294–300.
Betticher, D. C., White, G. R. M., Vonlanthen, S., Liu, X., Kappeler, A., Altermatt, H., Thatcher, N. & Heighway, J. (1997). G1 control gene status is frequently altered in resectable non-small-cell lung cancer. Int J Cancer 74: 556–562.
Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K. W., Musgrove, E. A. & Sutherland, R. L. (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127–2133.
Chen, X., Bargonetti, J. & Prives, C. (1995). p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 55: 4257–4263.
Del Sal, G., Murphy, M., Ruaro, E., Lazarevic, D., Levine, A. & Schneider, C. (1996). Cyclin D1 and p21/waf1 are involved in p53 growth suppression. Oncogene 12: 177–185.
Fearon, E. R. & Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61: 759–767.
Filmus, J., Robles, A. I., Shi, W., Wong, M. J., Colombo, L. L. & Conti, C. (1994). Induction of cyclin D1 overexpression by activated. ras. Oncogene 9: 3627–3633.
Gerdes, J., Lemke, H., Baisch, H., Wacker, H., Schwab, U. & Stein, H. (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715.
Hannon, G. J. & Beach, D. (1994). p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371: 257–261.
Harada, M., Dosaka-Akita, H., Miyamoto, H., Kuzumaki, N. & Kawakami, Y. (1992). Prognostic significance of the expression of ras oncogene product in non-small-cell lung cancer. Cancer 69: 72–77.
Hinds, P. W., Dowdy, S. F., Eaton, E. N., Arnold, A. & Weinberg, R. A. (1994). Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91: 709–713.
Jiang, W., Tomita, N., Zhang, Y., Lu, S. & Weinstein, B. (1992). Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52: 2980–2983.
Jiang, W., Kahn, S. M., Zhou, P., Zhang, Y., Cacace, A. M., Infante, A. S., Doi, S., Santella, R. M. & Weinstein, I. B. (1993). Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8: 3447–3457.
Kinoshita, I., Dosaka-Akita, H., Mishina, T., Akie, K., Nishi, M., Hiroumi, H., Hommura, F. & Kawakami, Y. (1996). Altered p16INK4 and retinoblastoma protein status in non-small-cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 56: 5557–5562.
Lovec, H., Sewing, A., Lucibello, F. C., Müller, R. & Möröy, T. (1994). Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9: 323–326.
Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. (1994a). Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 9: 707–718.
Lukas, J., Müller, H., Bartkova, J., Spitkovsky, D., Kjerulff, A. A., Jansen-Durr, P., Strauss, M. & Bartek, J. (1994b). DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell’s requirement for cyclin D1 function in G1. J Cell Biol 125: 625–638.
Lukas, J., Parrr, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G. & Bartek, J. (1995). Retinoblastoma-protein dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503–506.
McIntosh, G. G., Anderson, J. J., Milton, I., Steward, M., Parr, A. H., Thomas, M. D., Henry, J. A., Angus, B., Lennard, T. W. J. & Horne, C. H. W. (1995). Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11: 885–891.
Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Gaeta, P., La Rocca, R., Merlo, G., Chella, A., Angeletti, C. A., Palma, P. D. & Bevilacqua, G. (1998). Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small-cell lung cancer. Int J Cancer 75: 187–192.
Marhin, W. W., Hei, Y., Chen, S., Jiang, Z., Gallie, B. L., Phillips, R. A. & Penn, L. Z. (1996). Loss of Rb and myc activation co-operate to suppress cyclin D1 and contribute to transformation. Oncogene 12: 43–52.
Mate, J. L., Ariza, A., Aracil, C., Lopez, D., Isamat, M., Perez-Piteira, J. & Navas-Palacios, J. J. (1996). Cyclin D1 overexpression in non-small-cell lung carcinoma: correlation with Ki-67 labelling index and poor cytoplasmic differentiation. J Pathol 180: 395–399.
Matsushime, H., Roussel, M. F., Ashmun, R. A. & Sherr, C. J. (1991). Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65: 701–713.
Mineta, H., Borg, Å, Dictor, M., Wahlberg, P. & Wennerberg, J. (1997). Correlation between p53 mutation and cyclin D1 amplification in head and neck squamous cell carcinoma. Oral Oncol 33: 42–46.
Motokura, T., Bloom, T., Kim, H. G., Juppner, H., Ruderman, J. V., Kronenberg, H. M. & Arnold, A. (1991). A novel cyclin encoded by a bcl-1-linked candidate oncogene. Nature 350: 512–515.
Müller, H., Lukas, J., Schneider, A., Warthoe, P., Bartek, J., Eilers, M. & Strauss, M. (1994). Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 91: 2945–2949.
Naitoh, H., Shibata, J., Kawaguchi, A., Kodama, M. & Hattori, T. (1995). Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 146: 1161–1169.
Nakagawa, H., Wang, T. C., Zukerberg, L., Odze, R., Togawa, K., May, G. H. W., Wilson, J. & Rustgi, A. K. (1997). The targeting of the cyclin D1 oncogene by an Epstein–Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene 14: 1185–1190.
Nikaido, T., Li, S., Shiozawa, T. & Fujii, S. (1996). Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 78: 1248–1253.
Nishida, N., Fukuda, Y., Komeda, T., Kita, R., Sando, T., Furukawa, M., Amenomori, M., Shibagaki, I., Nakao, K., Ikenaga, M. & Ishizaki, K. (1994). Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 54: 3107–3110.
Nishio, M., Koshikawa, T., Yatabe, Y., Kuroishi, T., Suyama, M., Nagatake, M., Sugiura, T., Ariyoshi, Y., Mitsudomi, T., Takahashi, T. & Takahashi, T. A. (1997). Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small-cell lung cancers. Clin Cancer Res 3: 1051–1058.
Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J., Bernards, R., DeCaprio, J. A. & Ewen, M. (1997). Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386: 177–181.
Ravitz, M. J., Yan, S., Dolce, C., Kinniburgh, A. J. & Wenner, C. E. (1996). Differential regulation of p27 and cyclin D1 by TGF-β and EGF in C3H 10T1/2 mouse fibroblasts. J Cell Physiol 168: 510–520.
Serrano, M., Hannon, G. J. & Beach, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707.
Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D. J. & Rollins, B. J. (1995). Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505–509.
Sherr, C. J. (1996). Cancer cell cycles. Science 274: 1672–1677.
Sofer-Levi, Y. & Resnitzky, D. (1996). Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E. Oncogene 13: 2431–2437.
Spitkovsky, D., Steiner, Gopalkrishnan, R. V., Eilers, M. & Jansen-Dürr, P. (1995). The role of p53 in coordinated regulation of cyclin D1 and p21 gene expression by the adenovirus E1A and E1B oncogenes. Oncogene 10: 2421–2425.
Tanaka, H., Fujii, Y., Hirabayashi, H., Miyoshi, S., Sakaguchi, M., Yoon, H. & Matsuda, H. (1998). Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int J Cancer 79: 111–115.
Uchimura, K., Endo, K., Fujinuma, H., Zukerberg, L., Arnold, A. & Motokura, T. (1996). Oncogenic collaboration of the cyclin D1 (PRAD1, bcl-1) gene with a mutated p53 and an activated ras oncogene in neoplastic transformation. Jpn J Cancer Res 87: 459–465.
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A. & Schmidt, E. V. (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669–671.
Weinberg, R. A. (1995). The retinoblastoma protein and cell cycle control. Cell 81: 323–330.
WHO (1982). Histological Typing of Lung Tumors, 2nd edn. pp. 25–26. World Health Organization: Geneva
Zhu, X., Ohtsubo, M., Böhmer, R. M., Roberts, J. M. & Assoian, R. K. (1996). Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 133: 391–403.
About this article
Cite this article
Mishina, T., Dosaka-Akita, H., Kinoshita, I. et al. Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome. Br J Cancer 80, 1289–1295 (1999) doi:10.1038/sj.bjc.6990500
- cyclin D1
- p16/RB pathway
- Ki-67 index
- clinical outcome
- non-small-cell lung cancers
Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer
Lung Cancer (2018)
The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action
Molecular Pharmacology (2013)
The Role of Cyclin D1 Expression and Patient's Survival in Non–Small-Cell Lung Cancer: A Systematic Review With Meta-Analysis
Clinical Lung Cancer (2012)
Journal of Experimental & Clinical Cancer Research (2011)